// App-Quantinova.ai

BSH2020‐PO‐206 : Alemtuzumab containing renal transplant protocols are associated with late onset EBV+ PTLD, with poorer overall survival

Researchers

Presenter

  • M. Fareen

Principal Investigators

  • G. Lucisano

  • M. Willicombe

  • L. Cook

Medical Centers

  • School of Medicine

  • Imperial College Renal and Transplant Centre, London, United Kingdom

  • Department of Haematology, Imperial College London,

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Post-transplant lymphoproliferative disorder

Biomarkers

  • N/A

Drug/Treatment

  • Alemtuzumab

Outcome

  • N/A

Study Design

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved